Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 281.13M P/E - EPS this Y -19.40% Ern Qtrly Grth -
Income -101.74M Forward P/E -2.09 EPS next Y -7.80% 50D Avg Chg -4.00%
Sales 36.53M PEG - EPS past 5Y - 200D Avg Chg -40.00%
Dividend N/A Price/Book 1.23 EPS next 5Y - 52W High Chg -63.00%
Recommedations 1.60 Quick Ratio 7.33 Shares Outstanding 106.74M 52W Low Chg 29.00%
Insider Own 13.51% ROA -17.01% Shares Float 46.04M Beta 0.84
Inst Own 88.54% ROE -40.49% Shares Shorted/Prior 10.63M/8.88M Price 3.18
Gross Margin -215.38% Profit Margin -278.55% Avg. Volume 188,188 Target Price 17.57
Oper. Margin -644.69% Earnings Date May 7 Volume 67,066 Change -2.45%
About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics, Inc. News
04/01/24 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/20/24 Tango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results
03/18/24 Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
03/06/24 Tango Therapeutics to Participate in Upcoming Investor Conferences
03/05/24 Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
07:04 AM Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
01/31/24 Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01/04/24 Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
07:00 AM Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
12/13/23 Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%
11/13/23 Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
11/08/23 Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates
11/08/23 Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
11/07/23 Tango Therapeutics to Present at the Jefferies London Healthcare Conference
09/18/23 Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09/06/23 Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
09/05/23 Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08/29/23 Tango Therapeutics Announces Updates to Its Board of Directors
08/28/23 Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
08/10/23 Tango Therapeutics Announces $80 million Private Placement Financing
TNGX Chatroom

User Image Doorkey Posted - 04/16/24

$TNGX -$ -$

User Image Stock_Titan Posted - 1 month ago

$TNGX Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/TNGX/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-djbqgayxo1w2.html

User Image Chauncy_Peppertooth Posted - 03/27/24

$TNGX Anyone notice BMS is laying off half of the MRTX staff today? Tango’s closest competitor in PRMT5 looks like they may be hitting a snag giving us time to catch up…

User Image Quantumup Posted - 03/21/24

Citi⬆️ $IDYA $60 was $40/rBuy+Top Pick~doesn't believe rally over: +s IDE161 in HRD solid tumors2value; believe further upside will be catalyzed by multi-readouts4daro; reg guide on a pivotal study design; updates from IDE161 Ph1/2/daro 1L MUM pivotal ('24); joint strategy w/ $AMGN $imcr $tngx $bmy

User Image yungbiotech_OG Posted - 03/19/24

$TNGX

User Image Stock_Titan Posted - 03/18/24

$TNGX Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights https://www.stocktitan.net/news/TNGX/tango-therapeutics-reports-fourth-quarter-and-full-year-2023-2a9tgzmfxp89.html

User Image RiskVsReward Posted - 03/16/24

$TNGX Nice chart here.🚨

User Image yungbiotech_OG Posted - 03/16/24

$TNGX

User Image Doorkey Posted - 03/12/24

$TNGX Hasn't gone as planed. Testing my resolve.

User Image Quantumup Posted - 03/08/24

BTIG🏁 $IDYA Buy/$55~Co has a robust pipeline of FiC molecules in onc mkts + Strong Balance Sheet. Daro' has shown +VE clin data in the untapped HLA-A2(-) uveal melanoma pt pop, who are ineligible for tx w/ $IMCR 's Buy/$91) KIMMTRAK; +VE'ly views IDE397 as differentiated/pot BiC. $amgn $bmy $tngx

User Image Stock_Titan Posted - 03/06/24

$TNGX Tango Therapeutics to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/TNGX/tango-therapeutics-to-participate-in-upcoming-investor-4ckfuujsqfhs.html

User Image Stock_Titan Posted - 03/05/24

$TNGX Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 https://www.stocktitan.net/news/TNGX/tango-therapeutics-to-highlight-preclinical-data-on-precision-3a2to1z5ipuq.html

User Image TAFox Posted - 02/28/24

$TNGX started a position here.

User Image OutTheCloset Posted - 02/15/24

$TNGX not liking the chart atm

User Image Quantumup Posted - 02/12/24

Piper Sandler🏁 $TNGX OW/$18 $TNGX' MTA-cooperative PRMT5 inhibitor portfolio is well positioned w/in precision oncology. PS sees initial clinical data from MRTX1719 and AMG 193 as establishing *unambiguous clinical PoC 4 class; sees TNG908/TNG462 as pot FiC/BiC opp. $BMY $MRTX $AMGN $IDYA

User Image Sixth_Sense Posted - 02/10/24

$RPTX - 335M $TNGX - 1.26B $IDYA - 3.31B Own all 3 and love all 3, but from a Risk / Reward standpoint, I’m heavy in RPTX. Synthetic Lethality is still scratching the surface of its potential and each of these names are BO candidates in the near future. Some nice deals already in place, but sky is the limit for more deals to come as well. Good luck fellow longs!

User Image OutTheCloset Posted - 02/09/24

$TNGX what a run

User Image insiderbuyingselling Posted - 02/08/24

$TNGX new insider selling: 2776 shares. http://insiderbuyingselling.com/?t=TNGX

User Image insiderbuyingselling Posted - 02/08/24

$TNGX new insider selling: 3725 shares. http://insiderbuyingselling.com/?t=TNGX

User Image insiderbuyingselling Posted - 02/08/24

$TNGX new insider selling: 9138 shares. http://insiderbuyingselling.com/?t=TNGX

User Image BobBuran Posted - 01/25/24

Thursday Dow opens +95 and we open +$837 with $SWVL and $TNGX #stocks

User Image CPKC Posted - 01/24/24

Synthetic Lethality is the Antobody Drig Conjugate craze $IDYA $TNGX $RPTX

User Image Doozio Posted - 01/21/24

$TNGX chop chop huckleberries… 🧠⏰

User Image FonsieTrader Posted - 01/17/24

$TNGX breaking out

User Image JillAllend Posted - 01/17/24

$SEZL $TNGX $LEE $MYO ACCOUNT CHALLENGE UPDATE: Starting Balance: $3,700 Current Balance: $54,873 Goal: $100K by end of Feb. Watch out for our next alert!.,🌹 stocks-great-winning-trades-us-market.blogspot.com/2024/01/blog-post.html

User Image StockAutomatePro Posted - 01/14/24

$TNGX Looks like the stock is headed for a profitable period according to the chart. We alerted the BUY signal at $9.46 and we were able to close this one with profit at $10.94 🎯 See more details at StockAutomate.com

User Image tickeron Posted - 01/14/24

A.I.dvisor made a bullish call on $TNGX, netting in a 9.42% gain over 1 week https://srnk.us/go/4968810

User Image Pharmapower333 Posted - 01/12/24

$PMN Hear hear Investors Boston Investors Mike Gordon of Fenway Sports Group and Jeremy Sclar WS Development group who already owned 20% of Promis stock before entered with additional private financing of $20,4m into an agreement with Promis on their preferred shares. "Additionally on August 21,2023, the company entered into a Letter agreement with certain holders $TNGX $OCGN $GME $AMC

User Image FonsieTrader Posted - 01/12/24

$TNGX for next week

User Image Pharmapower333 Posted - 01/12/24

$PMN Bargain $8 worth stock at $2,44 Big Pharma Partnership in the making huge Pipeline @teambullish @PlayBookTrades @Alejos11 @CrytiCaII @ACInvestorBlog @topstockalerts @SadyK189 @OpenOutcrier @ZorTrades @Paraboljoker https://www.promisneurosciences.com/investors/news-events/press-releases/detail/215/promis-neurosciences-issues-letter-to-shareholders $TNGX $OCGN $AMC $GME

Analyst Ratings
Cantor Fitzgerald Overweight Apr 4, 24
HC Wainwright & Co. Buy Mar 20, 24
Piper Sandler Overweight Feb 12, 24
B. Riley Securities Buy Dec 8, 23
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Aug 8, 23
Wedbush Outperform May 10, 23
HC Wainwright & Co. Buy Mar 28, 23
HC Wainwright & Co. Buy Oct 20, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Boxer Capital, LLC Other Other Oct 13 Buy 6.96 1,250,000 8,700,000 8,198,642 10/17/23
Boxer Capital, LLC Other Other Oct 09 Sell 9.94 225,000 2,236,500 6,948,642 10/11/23
Boxer Capital, LLC Other Other Aug 11 Buy 5.15 475,000 2,446,250 743,542 08/15/23
Boxer Capital, LLC 10% Owner 10% Owner Oct 11 Buy 4.44 237,000 1,052,280 7,123,642 10/13/22
Boxer Capital, LLC 10% Owner 10% Owner Oct 04 Buy 3.87 182,000 704,340 7,053,642 10/06/22